The two companies have signed a collaboration and license agreement worth up to $615m, with Seattle Genetics committing $25m upfront and another $5m in equity.

US-based biotechnology company Unum Therapeutics entered a collaboration and license agreement with biotechnology company Seattle Genetics yesterday to develop and commercialise antibody treatments for cancer.

Seattle Genetics is set to make an upfront payment of $25m as part of the agreement, and has committed to contributing $5m to Unum’s next equity funding round. Option fees and milestone payments for the partnership could eventually total $615m.

Unum’s antibody-coupled T-cell receptor (ACTR) technology is able to instruct parts of the body’s own…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?